Monopar Therapeutics

NAQ:MNPR · US61023L2079

BiotechnologySmall

360° View

Value73

Price/Sales1

Price/Earnings81

Price/Book44

Dividend Yield—

Growth86

Revenue Growth—

Profit Growth87

Capital Growth43

TSR 52w72

Safety63

Leverage92

Liquidity1

Refinancing71

Combined88

Sentiment21

Analyst Opinions38

Pro Holdings75

Opinion Changes19

Market Pulse31

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQCM

Founded2015

Employees23

Websitemonopartx.com

ISINUS61023L2079

Last UpdateApr 2, 2026

Index & Theme

OncologyHealth DiagnosticsGenetic DisorderBiopharmaBiotechnologyDeveloper ToolsHealth CareTherapeutics

Description

Monopar Therapeutics Inc. (Monopar) is a clinical-stage biopharmaceutical company. The company is developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. The company’s Wilson disease product candidate is ALXN1840, a la…

Analysis

Monopar Therapeutics's 360° View rank of 67 places it above its peer average — better than 67% of its true peers.

It's a growth standout (86) and reasonably valued (73). On safety it is financially sound (63), and the market shows skeptical sentiment (21). Taken together, its Combined rank of 88 reads as among the strongest overall.

360° rank · history

1007550250

2026

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Monopar Therapeutics with its peers

Acumen Pharmaceuticals

NSQ:ABOS

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Dyne Therapeutics

NSQ:DYN

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Cartesian Therapeutics

NMQ:RNAC

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Gain Therapeutics

NMQ:GANX

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Protagonist Therapeutics

NMQ:PTGX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Praxis Precision Medicines

NSQ:PRAX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →